Early detection of bowel Cancer in the UK represents success of screening program
Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence…
Oncology
-
-
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
On 20 April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s anti-CD38 immunotherapy, felzartamab, in the…
-
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly. In June 2025,…
-
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application…
-
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
On 25 March, Merck (MSD) announced the $6.7bn acquisition of Terns Pharmaceuticals via a subsidiary, as part of its strategic…
-
Improving early detection and treatment of liver cancer
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour…
-
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race
In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T…
-
Multiple Myeloma Awareness Month: the current and future landscape
March is Multiple Myeloma (MM) Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM,…
-
Targeted therapies to join chemo as oncology treatment backbone
In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens…
-
Theranostics earmarked as “the future” of radiopharmaceuticals
As the oncology market enters a new era of growth, targeted therapies across several modalities are transforming the treatment paradigm.…
